Company Number: 14705577

Analysis Date: 2025-07-20 16:28 UTC

1. Credit Opinion: DECLINE
   Luxe Pharma Limited is a newly incorporated micro-entity with a very limited operating history (since March 2023). The latest accounts show net liabilities of £3,571 and negative net current assets of £3,420, indicating a working capital deficiency. There is no evidence of revenue or profitability reported, and the company has no employees. The director is also the sole significant controller, which concentrates risk. These factors combined raise concerns about the company’s ability to service debt or meet commercial obligations reliably at this stage.

2. Financial Strength:
   The balance sheet is weak, with fixed assets of only £1,289 and current assets of £8,191 offset by current liabilities of £11,611. The net liabilities position (£3,571) reflects accumulated losses or initial capital shortfall. The negative working capital (current assets less current liabilities) indicates potential liquidity stress. No equity injections or financial reserves appear evident beyond initial funding. The absence of audit or detailed financials limits insight into underlying cash flows or profitability prospects.

3. Cash Flow Assessment:
   Given the negative net current assets and lack of employees, cash flow generation appears minimal or negative. The company likely relies on shareholder funds or external financing to meet short-term obligations. The accruals and deferred income of £1,440 suggest some liabilities not yet settled. Without operating profits or positive cash inflows from customers, liquidity risk is high. Monitoring cash balances and creditor payment terms will be critical.

4. Monitoring Points:

• Subsequent trading results and cash flow statements to assess operational viability.
• Timely filing of next accounts and confirmation statement to monitor compliance and transparency.
• Changes in working capital and current liabilities levels to detect worsening liquidity.
• Any director or shareholder capital injections or external financing arrangements.
• Evidence of revenue growth or contract wins that improve credit profile.